Protocol Ledger

NCT04551300 · Phase II · COMPLETED

A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

Interventional Phase II clinical trial protocol NCT04551300 sponsored by Shanghai Alebund Pharmaceuticals Limited in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-13 Enrollment: 158 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04551300
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)158 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04551300
Protocol FieldVerified Registry Value
NCT IdentifierNCT04551300
Consolidated Lead SponsorShanghai Alebund Pharmaceuticals Limited
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment158 participants (ACTUAL)
Registered Start Date2020-10-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04551300
Hospital Research SiteLocationSite Profile
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
Renmin Hospital of Wuhan UniversityWuhan, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI